ARV Procurement Working Group
Our Contacts
Business Online, Newyork, 1st block
1234 Building no 8, floor 3
Email: info@consultaid.com
Phone: 5586 554 558
APWG supports the ARV market in low- and middle-income countries through procurement, strategically managed demand and reduced fragmentation.
Lopinavir/Ritonavir 40mg/10mg Pellets and Granules and 100/25 mg Tablets
Due to the increasing uptake of paediatric LPV/r formulations, the ARV Procurement Working Group (APWG) has developed the below dashboard to provide information on supply availability in the coming 18-months.
Recommendations for country programs:
• Countries are strongly discouraged from stockpiling LPV/r oral pellets or oral granules and instead advised to
plan for more frequent, staggered small deliveries of large orders;
• Cipla and Mylan have invested in manufacturing capacity expansion to respond to the increased demand for lopinavir/ritonavir 40 mg/10 mg formulations as recommended in the WHO Consolidated HIV Guidelines;
• More info: https://www.arvprocurementworkinggroup.org/public/componenti/1395/files/APWGLPVrMemotoSuppliersandCountries_Jan2019.pdf
